Literature DB >> 17631755

Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: an open label observational study.

N Assous, L Gossec, M Dougados, A Kahan, Y Allanore.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17631755

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  1 in total

1.  Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.

Authors:  Moetaza M Soliman; Kimme L Hyrich; Mark Lunt; Kath D Watson; Deborah P M Symmons; Darren M Ashcroft
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-08       Impact factor: 4.794

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.